All In Biotech

Drug Trial Radar · NCT06253546

Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia

A Phase 1, Single Dose, Parallel Cohort Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TV-44749, Olanzapine for Extended-Release Injectable Suspension for Subcutaneous Use, in Chinese Patients With Schizophrenia

Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

24

Actual

Start

Mar 28, 2024

Primary completion

Jun 12, 2025

Study completion Jun 12, 2025

Sponsor

Sponsor type
Industry
First posted
Feb 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To evaluate the safety and tolerability of single doses of TV-44749 for subcutaneous (sc) use in Chinese participants with schizophrenia. Secondary Objectives: * To evaluate the pharmacokinetics (PK) of single doses of TV-44749 administered sc. * To evaluate the pharmacokinetics of oral olanzapine tablets following multiple dose administration. * To monitor the safety and tolerability of multiple doses of oral olanzapine tablets given in the study.

Conditions

  • Schizophrenia

Interventions

  • TV-44749 318mgDrug

    Pharmaceutical form: extended-release injectable suspension Route of administration: subcutaneous injection

  • Oral Olanzapine 10mg/dayDrug

    Pharmaceutical form: tablet Route of administration: oral

  • TV-44749 425mgDrug

    Pharmaceutical form: extended-release injectable suspension Route of administration: subcutaneous injection

  • Oral Olanzapine 15mg/dayDrug

    Pharmaceutical form: tablet Route of administration: oral

  • TV-44749 531mgDrug

    Pharmaceutical form: extended-release injectable suspension Route of administration: subcutaneous injection

  • Oral Olanzapine 20mg/dayDrug

    Pharmaceutical form: tablet Route of administration: oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Period 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Day 1 Up to Day 43
  2. Period 2: Number of Participants With Treatment Emergent SAEsTime frame: Day 1 Up to Day 43
  3. Period 2: Number of Participants With Injection Site AEsTime frame: Day 1 Up to Day 43

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Teva Investigational Site 88049

    Beijing, China

  • Teva Investigational Site 88048

    Beijing, China

  • Teva Investigational Site 88047

    Guangzhou, China

  • Teva Investigational Site 88046

    Shanghai, China

  • Teva Investigational Site 88050

    Wuhan, China

  • Teva Investigational Site 88056

    Xi'an, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.